Aridis Pharmaceuticals has executed an agreement to sell AR-501, a therapeutic for chronic bacterial lung infections in cystic fibrosis, for $6.5 million plus royalties.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.